Details of the Drug

General Information of Drug (ID: DMHIDUE)

• Drug Name: Phenelzine
• Synonyms: Fenelzina; Fenelzyna; Fenelzyne; Phenelezine; Phenelzinum; Phenethylhydrazine; Phenylethylhydrazine; Fenelzyna [Polish]; Fenelzyne [Polish]; W1544; Beta-Phenylethylhydrazine; Fenelzina [INN-Spanish]; Nardelzine (TN); Nardil (TN); Phenelzine (BAN); Phenelzine [INN:BAN]; Phenelzinum [INN-Latin]; Phenylethyl hydrazine-HCl; W 1544-A; 1-Hydrazino-2-phenylethane; 2-Phenethylhydrazine; 2-Phenylethylhydrazine

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Skin imperfections	EK71	Patented	[2]

• Therapeutic Class: Antidepressants
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 136.19
  Logarithm of the Partition Coefficient (xlogp); 1.2
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 19.8 mcg/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 43 min [3]
  Elimination: The elimination of the administered dose is mainly composed of the phenelzine metabolites, phenylacetic acid and parahydroxyphenylacetic acid that constitute 79% of the dose found in the urine in the first 96 hours [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 11.6 hours [3]
• Chemical Identifiers:
  Formula: C8H12N2
  IUPAC Name: 2-phenylethylhydrazine
  Canonical SMILES: C1=CC=C(C=C1)CCNN
  InChI: InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
  InChIKey: RMUCZJUITONUFY-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3675
  ChEBI ID: CHEBI:8060
  CAS Number: 51-71-8
  DrugBank ID: DB00780
  TTD ID: D0P9AC
  INTEDE ID: DR1272
  ACDINA ID: D00524
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase (MAO)	TT32XQJ	NOUNIPROTAC	Inhibitor	[2]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[6]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[6]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Gene/Protein Processing	[7]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[8]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[8]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Gene/Protein Processing	[9]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[10]

Molecular Expression Atlas of This Drug

• The Studied Disease: Depression
• ICD Disease Classification: 6A70-6A7Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Monoamine oxidase type B (MAO-B)	DTT	MAOB	2.65E-02	1.12E-02	0.07
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.96E-01	-3.17E-03	-1.84E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Phenelzine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Phenelzine and Sertraline.	Depression [6A70-6A7Z]	[11]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Phenelzine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[12]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Phenelzine and Vilazodone.	Depression [6A70-6A7Z]	[13]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Phenelzine and Nefazodone.	Depression [6A70-6A7Z]	[13]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Phenelzine and Vortioxetine.	Depression [6A70-6A7Z]	[11]
Isocarboxazid	DMAF1NB	Major	Additive hypertensive effects by the combination of Phenelzine and Isocarboxazid.	Depression [6A70-6A7Z]	[14]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Phenelzine and Milnacipran.	Depression [6A70-6A7Z]	[13]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Phenelzine and Desvenlafaxine.	Depression [6A70-6A7Z]	[13]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Phenelzine and Clomipramine.	Depression [6A70-6A7Z]	[12]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Phenelzine and Doxepin.	Depression [6A70-6A7Z]	[15]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Phenelzine and Esketamine.	Depression [6A70-6A7Z]	[16]

Coadministration of a Drug Treating the Disease Different from Phenelzine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Phenelzine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[12]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Phenelzine and Repaglinide.	Acute diabete complication [5A2Y]	[17]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Phenelzine and Glibenclamide.	Acute diabete complication [5A2Y]	[17]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Phenelzine and Tolazamide.	Acute diabete complication [5A2Y]	[17]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Phenelzine and Insulin-glulisine.	Acute diabete complication [5A2Y]	[17]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Phenelzine and Insulin-aspart.	Acute diabete complication [5A2Y]	[18]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Phenelzine and Glipizide.	Acute diabete complication [5A2Y]	[17]
Phenyltoloxamine	DMKAEQW	Moderate	Additive CNS depression effects by the combination of Phenelzine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[19]
Tripelennamine	DMZBU15	Moderate	Additive CNS depression effects by the combination of Phenelzine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[19]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Phenelzine and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[20]
Bepridil	DM0RKS4	Moderate	Additive hypotensive effects by the combination of Phenelzine and Bepridil.	Angina pectoris [BA40]	[20]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Phenelzine and Nifedipine.	Angina pectoris [BA40]	[20]
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Phenelzine and Levalbuterol.	Asthma [CA23]	[21]
Pirbuterol	DMI5678	Moderate	Additive hypertensive effects by the combination of Phenelzine and Pirbuterol.	Asthma [CA23]	[22]
Ephedrine	DMMV0KW	Moderate	Decreased metabolism of Phenelzine caused by Ephedrine mediated inhibition of non-CYP450 enzyme.	Asthma [CA23]	[23]
Salbutamol	DMN9CWF	Moderate	Additive hypertensive effects by the combination of Phenelzine and Salbutamol.	Asthma [CA23]	[21]
Formoterol	DMSOURV	Moderate	Additive hypertensive effects by the combination of Phenelzine and Formoterol.	Asthma [CA23]	[22]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of hyperpyrexia by the combination of Phenelzine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[20]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Phenelzine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[12]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Phenelzine and Droxidopa.	Autonomic nervous system disorder [8D87]	[24]
Pseudoephedrine	DMIVJ0D	Major	Additive hypertensive effects by the combination of Phenelzine and Pseudoephedrine.	Breathing abnormality [MD11]	[20]
Olodaterol	DM62B78	Moderate	Additive hypertensive effects by the combination of Phenelzine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[22]
Vilanterol	DMF5EK1	Moderate	Additive hypertensive effects by the combination of Phenelzine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Salmeterol	DMIEU69	Moderate	Additive hypertensive effects by the combination of Phenelzine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[22]
Indacaterol	DMQJHR7	Moderate	Additive hypertensive effects by the combination of Phenelzine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[22]
Arformoterol	DMYM974	Moderate	Additive hypertensive effects by the combination of Phenelzine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[22]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Phenelzine and Levomilnacipran.	Chronic pain [MG30]	[13]
Isoproterenol	DMK7MEY	Moderate	Additive hypertensive effects by the combination of Phenelzine and Isoproterenol.	Conduction disorder [BC63]	[21]
Cocaine	DMSOX7I	Major	Increased risk of hyperpyrexia by the combination of Phenelzine and Cocaine.	Corneal disease [9A76-9A78]	[25]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Phenelzine and Ethanol.	Cystitis [GC00]	[26]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Phenelzine and Cyclandelate.	Dementia [6D80-6D8Z]	[20]
LEVONORDEFRIN	DMWDJ0H	Moderate	Additive hypertensive effects by the combination of Phenelzine and LEVONORDEFRIN.	Discovery agent [N.A.]	[27]
Tetrabenazine	DMYWQ0O	Major	Additive hypertensive effects by the combination of Phenelzine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[28]
Deutetrabenazine	DMUPFLI	Major	Additive hypertensive effects by the combination of Phenelzine and Deutetrabenazine.	Dystonic disorder [8A02]	[28]
Diphenhydramine	DMKQTBA	Moderate	Additive CNS depression effects by the combination of Phenelzine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[19]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Phenelzine and Ethacrynic acid.	Essential hypertension [BA00]	[29]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Phenelzine and Phenoxybenzamine.	Essential hypertension [BA00]	[20]
Guanethidine	DM9NSWT	Moderate	Antagonize the effect of Phenelzine when combined with Guanethidine.	Essential hypertension [BA00]	[30]
Mephentermine	DMFJH5Q	Major	Additive hypertensive effects by the combination of Phenelzine and Mephentermine.	Essential hypertension [BA00]	[20]
Oxymetazoline	DM8ZXT6	Moderate	Decreased metabolism of Phenelzine caused by Oxymetazoline mediated inhibition of non-CYP450 enzyme.	Eyelid inflammatory disorder [9A02]	[23]
Solifenacin	DMG592Q	Minor	Additive anticholinergic effects by the combination of Phenelzine and Solifenacin.	Functional bladder disorder [GC50]	[31]
Propantheline	DM2EN6G	Minor	Additive anticholinergic effects by the combination of Phenelzine and Propantheline.	Gastric ulcer [DA60]	[31]
Dobutamine	DMD1B8Z	Moderate	Additive hypertensive effects by the combination of Phenelzine and Dobutamine.	Heart failure [BD10-BD1Z]	[20]
Nesiritide	DMFOIA8	Moderate	Additive hypotensive effects by the combination of Phenelzine and Nesiritide.	Heart failure [BD10-BD1Z]	[20]
Chlorothiazide	DMLHESP	Moderate	Additive hypotensive effects by the combination of Phenelzine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[20]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Phenelzine and Bumetanide.	Heart failure [BD10-BD1Z]	[20]
Tetrahydrozoline	DMT57WC	Moderate	Decreased metabolism of Phenelzine caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme.	Herpes simplex infection [1F00]	[23]
Procarbazine	DMIK367	Major	Additive hypertensive effects by the combination of Phenelzine and Procarbazine.	Hodgkin lymphoma [2B30]	[14]
Maraviroc	DMTL94F	Moderate	Additive hypotensive effects by the combination of Phenelzine and Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Phenelzine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[20]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Phenelzine and Eprosartan.	Hypertension [BA00-BA04]	[20]
Aliskiren	DM1BV7W	Moderate	Additive hypotensive effects by the combination of Phenelzine and Aliskiren.	Hypertension [BA00-BA04]	[20]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Phenelzine and Captopril.	Hypertension [BA00-BA04]	[20]
Methyldopa	DM5I621	Major	Decreased metabolism of Phenelzine caused by Methyldopa mediated inhibition of non-CYP450 enzyme.	Hypertension [BA00-BA04]	[30]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Phenelzine and Levamlodipine.	Hypertension [BA00-BA04]	[20]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Phenelzine and TAK-491.	Hypertension [BA00-BA04]	[20]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Phenelzine and Fenoldopam.	Hypertension [BA00-BA04]	[20]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Phenelzine and Indapamide.	Hypertension [BA00-BA04]	[20]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Phenelzine and Trichlormethiazide.	Hypertension [BA00-BA04]	[20]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Phenelzine and Diazoxide.	Hypertension [BA00-BA04]	[20]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Phenelzine and Perindopril.	Hypertension [BA00-BA04]	[20]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Phenelzine and Felodipine.	Hypertension [BA00-BA04]	[20]
Deserpidine	DMRH7CV	Moderate	Additive hypertensive effects by the combination of Phenelzine and Deserpidine.	Hypertension [BA00-BA04]	[32]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Phenelzine and Telmisartan.	Hypertension [BA00-BA04]	[20]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Phenelzine and Irbesartan.	Hypertension [BA00-BA04]	[20]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Phenelzine and Hydralazine.	Hypertension [BA00-BA04]	[20]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Phenelzine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[20]
Belladonna	DM2RBWK	Minor	Additive anticholinergic effects by the combination of Phenelzine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[31]
Dicyclomine	DMZSDGX	Minor	Additive anticholinergic effects by the combination of Phenelzine and Dicyclomine.	Irritable bowel syndrome [DD91]	[31]
Naphazoline	DMJFZDL	Moderate	Decreased metabolism of Phenelzine caused by Naphazoline mediated inhibition of non-CYP450 enzyme.	Itching [1F28-1G07]	[23]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Phenelzine and Almogran.	Migraine [8A80]	[33]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Phenelzine and Frovatriptan.	Migraine [8A80]	[33]
Rizatriptan	DMDJMA3	Major	Decreased metabolism of Phenelzine caused by Rizatriptan mediated inhibition of non-CYP450 enzyme.	Migraine [8A80]	[33]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Phenelzine and Naratriptan.	Migraine [8A80]	[33]
Lasmiditan	DMXLVDT	Major	Additive serotonergic effects by the combination of Phenelzine and Lasmiditan.	Migraine [8A80]	[13]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Phenelzine and Flibanserin.	Mood disorder [6A60-6E23]	[34]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Phenelzine and Thalidomide.	Multiple myeloma [2A83]	[35]
Ozanimod	DMT6AM2	Major	Decreased metabolism of Phenelzine caused by Ozanimod mediated inhibition of non-CYP450 enzyme.	Multiple sclerosis [8A40]	[36]
Dextroamphetamine	DMMIHVP	Major	Increased risk of hyperpyrexia by the combination of Phenelzine and Dextroamphetamine.	Narcolepsy [7A20]	[20]
Phenindamine	DMDTC7R	Moderate	Additive CNS depression effects by the combination of Phenelzine and Phenindamine.	Nasopharyngitis [CA00]	[19]
Dimenhydrinate	DM264B3	Minor	Additive anticholinergic effects by the combination of Phenelzine and Dimenhydrinate.	Nausea/vomiting [MD90]	[31]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Phenelzine and Promethazine.	Nausea/vomiting [MD90]	[20]
Cyclizine	DM9G7BS	Moderate	Additive CNS depression effects by the combination of Phenelzine and Cyclizine.	Nausea/vomiting [MD90]	[19]
Metoclopramide	DMFA5MY	Moderate	Increased risk of hyperpyrexia by the combination of Phenelzine and Metoclopramide.	Nausea/vomiting [MD90]	[37]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Phenelzine and Ondansetron.	Nausea/vomiting [MD90]	[19]
Bupropion	DM5PCS7	Major	Additive hypertensive effects by the combination of Phenelzine and Bupropion.	Nicotine use disorder [6C4A]	[32]
Phendimetrazine	DM6TS1N	Major	Increased risk of hyperpyrexia by the combination of Phenelzine and Phendimetrazine.	Obesity [5B80-5B81]	[20]
Amfepramone	DM9YSNQ	Major	Increased risk of hyperpyrexia by the combination of Phenelzine and Amfepramone.	Obesity [5B80-5B81]	[20]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Phenelzine and Sibutramine.	Obesity [5B80-5B81]	[13]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Phenelzine and Lorcaserin.	Obesity [5B80-5B81]	[38]
Benzphetamine	DMIJATC	Major	Increased risk of hyperpyrexia by the combination of Phenelzine and Benzphetamine.	Obesity [5B80-5B81]	[20]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Phenelzine and Dexfenfluramine.	Obesity [5B80-5B81]	[13]
Propylhexedrine	DMTBW2O	Moderate	Decreased metabolism of Phenelzine caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme.	Obesity [5B80-5B81]	[23]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Phenelzine and Polythiazide.	Oedema [MG29]	[20]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Phenelzine and Lofexidine.	Opioid use disorder [6C43]	[20]
Apraclonidine	DMO4PVE	Major	Additive hypertensive effects by the combination of Phenelzine and Apraclonidine.	Optic nerve disorder [9C40]	[32]
Methamphetamine	DMPM4SK	Major	Additive hypertensive effects by the combination of Phenelzine and Methamphetamine.	Pain [MG30-MG3Z]	[39]
Biperiden	DME78OA	Minor	Additive anticholinergic effects by the combination of Phenelzine and Biperiden.	Parkinsonism [8A00]	[40]
Levodopa	DMN3E57	Major	Additive hypertensive effects by the combination of Phenelzine and Levodopa.	Parkinsonism [8A00]	[20]
Dopamine	DMPGUCF	Major	Increased risk of hyperpyrexia by the combination of Phenelzine and Dopamine.	Parkinsonism [8A00]	[20]
Ritodrine	DM4V6RL	Moderate	Additive hypertensive effects by the combination of Phenelzine and Ritodrine.	Preterm labour/delivery [JB00]	[22]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Phenelzine and Terazosin.	Prostate hyperplasia [GA90]	[20]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Phenelzine and Silodosin.	Prostate hyperplasia [GA90]	[20]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Phenelzine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[20]
Selexipag	DMAHSU0	Moderate	Additive hypotensive effects by the combination of Phenelzine and Selexipag.	Pulmonary hypertension [BB01]	[20]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Phenelzine and Tolazoline.	Pulmonary hypertension [BB01]	[20]
Epoprostenol	DMUTYR2	Moderate	Additive hypotensive effects by the combination of Phenelzine and Epoprostenol.	Pulmonary hypertension [BB01]	[20]
Iloprost	DMVPZBE	Moderate	Additive hypotensive effects by the combination of Phenelzine and Iloprost.	Pulmonary hypertension [BB01]	[20]
Mesoridazine	DM2ZGAN	Moderate	Additive CNS depression effects by the combination of Phenelzine and Mesoridazine.	Schizophrenia [6A20]	[20]
Trifluoperazine	DMKBYWI	Moderate	Additive CNS depression effects by the combination of Phenelzine and Trifluoperazine.	Schizophrenia [6A20]	[20]
Avanafil	DM75CXN	Moderate	Additive hypotensive effects by the combination of Phenelzine and Avanafil.	Sexual dysfunction [HA00-HA01]	[20]
Tadalafil	DMJZHT1	Moderate	Additive hypotensive effects by the combination of Phenelzine and Tadalafil.	Sexual dysfunction [HA00-HA01]	[20]
Vardenafil	DMTBGW8	Moderate	Additive hypotensive effects by the combination of Phenelzine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[20]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Phenelzine and Papaverine.	Tonus and reflex abnormality [MB47]	[20]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Phenelzine and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[17]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Phenelzine and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[17]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Phenelzine and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[17]
Chlorpheniramine	DM5URA2	Moderate	Additive CNS depression effects by the combination of Phenelzine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[19]
Methdilazine	DMAUHQX	Moderate	Additive CNS depression effects by the combination of Phenelzine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[20]
Brompheniramine	DMFOVSD	Moderate	Additive CNS depression effects by the combination of Phenelzine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[19]
Acrivastine	DMTIGA0	Moderate	Additive CNS depression effects by the combination of Phenelzine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[19]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Edetate disodium	E00186	8759	Complexing agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Phenelzine 15 mg tablet	15 mg	Oral Tablet	Oral
Phenelzine Sulfate 15mg/tablet tablet	15mg/tablet	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7266).
• [2] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [3] New Zealand report
• [4] Robinson DS, Cooper TB, Jindal SP, Corcella J, Lutz T: Metabolism and pharmacokinetics of phenelzine: lack of evidence for acetylation pathway in humans. J Clin Psychopharmacol. 1985 Dec;5(6):333-7.
• [5] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [6] An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
• [7] Low serum pseudocholinesterase levels complicating treatment with phenelzine. Br Med J. 1969 Aug 30;3(5669):510-2. doi: 10.1136/bmj.3.5669.510.
• [8] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [9] Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. 2015 Mar 25;230:9-20.
• [10] Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
• [11] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
• [12] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
• [13] Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
• [14] Bazire SR "Sudden death associated with switching monoamine oxidase inhibitors." Drug Intell Clin Pharm 20 (1986): 954-6. [PMID: 3816543]
• [15] Spiker DG, Pugh DD "Combining tricyclic and monoamine oxidase inhibitor antidepressants." Arch Gen Psychiatry 33 (1976): 828-30. [PMID: 942286]
• [16] Cerner Multum, Inc. "Australian Product Information.".
• [17] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [18] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
• [19] Canadian Pharmacists Association.
• [20] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [21] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
• [22] Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
• [23] Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
• [24] Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
• [25] Product Information. Cocaine Hydrochloride Nasal (cocaine nasal). Genus Lifesciences Inc., Allentown, PA.
• [26] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [27] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
• [28] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [29] Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
• [30] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
• [31] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [32] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
• [33] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
• [34] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [35] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [36] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [37] Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9. [PMID: 6541544]
• [38] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [39] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
• [40] Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.